THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration to Advance Oncology Therapeutics.

CDDF
Cancer Drug Development Forum

TOGETHER, WE IDENTIFY AND OVERCOME CHALLENGES IN THE **DEVELOPMENT** AND **DELIVERY** OF **CANCER DRUGS**

OUR MISSION

The Cancer Drug Development Forum (CDDF) is the leading non-competitive drug development platform in Europe whose sole objective is to stimulate advancement in cancer drug development and access.

HOW WE ADVANCE OUR MISSION

The CDDF provides a unique platform to facilitate collaboration between stakeholders to increase efficiency in cancer drug development.

Our integrative approach aims to bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to improve cancer treatment.

The Cancer Drug Development Forum

INITIATIVES

For years, the Cancer Drug Development Forum (CDDF) has focused on developing initiatives that **accelerate effective drug development** in oncology treatment and shorten time to market, and time to patient access.

CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into **a productive dialogue in a neutral, non-competitive space.**

CDDF holds multiple activities and initiatives in **collaboration with regulators** from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and other regulatory agencies, **academic researchers** from around the globe, **pharmaceutical companies**, and **patient advocates.**

The Cancer Drug Development Forum (CDDF) Spring Conference is a unique annual meeting. This multi-stakeholder, interactive 3-day meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The responsive nature of the CDDF platform means that **programs can be quickly initiated or adapted to reflect current and pressing issues**. Following the outbreak of the COVID-19 pandemic, CDDF rapidly organised a webinar to discuss the potential impact of the virus on both cancer care delivery and clinical trial performance.

Since its inception, CDDF has proved to be a **visionary force within the cancer drug development field** addressing topics such as : immuno-oncology, the use of real-world data in cancer drug development, or improving outcomes for children and adolescents with cancer through the **ACCELERATE platform** launched in 2013.

The CDDF continues **to pioneer progress in cancer drug treatments** by exploring the potential impact of digital health and artificial intelligence on cancer patients at forthcoming workshops.

CDDF publishes reports prepared from workshops discussions, conference presentations and lecture briefings **to increase knowledge of the challenges and opportunities in cancer drug development.**

CDDF WORKSHOPS ARE **USEFUL** TO GET THE PERSPECTIVE OF **REGULATORS, HTA, INDUSTRY, ACADEMICS** AND **PATIENTS.** EVERYONE IS GIVEN THE CHANCE TO **CONTRIBUTE**

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs.

Representing a range of perspectives within the drug development process, these distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists, who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS

Prof. John Smyth
Chairperson

Prof. Ruth Plummer
Deputy Chairperson

Prof. Axel Glasmacher
Treasurer

Prof. Jaap Verweij
Board Member and Managing Director

Prof. Francesco De Lorenzo
Board Member

Prof. Eva Skovlund
Board Member

Dr Catarina Edfjäll
Board Member

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.

Marjorie Recorbet
Director of operations

Hyunmin Park
Projects Coordinator

Magdaléna Strmeňová
Event Coordinator

Giorgia Campagnano
Event Coordinator

RECENT CDDF ACTIVITIES

The CDDF yearly conference and workshops focus on currently identified issues in cancer care and foster an exchange of expertise to accelerate and deliver cancer treatments.

CONFERENCE

CDDF 11TH YEARLY SPRING CONFERENCE

THE NETHERLANDS | 10-12 FEBRUARY 2020

OBJECTIVES

Understanding the relevance of individual components in combination therapies.

Analysis of progress made in previous CDDF workshop issues: biomarkers; patient access and involvement; Minimal Residual Disease; use of real-world data in drug development.

Understanding advances in, and the need for, innovation and collaboration in tumour agnostic drug-development.

Addressing regulation, progress and challenges in cellular therapies including car-T cell therapies.

Addressing regulatory guidance: EMA regulatory strategy 2025; envisioning product development for 2025; Industry perspectives on innovation and current topics in oncology.

KEY TAKE-HOME FROM THE CONFERENCE

The need to identify the best way forward to speed up drug approval whilst ensuring patient efficiency and safety and avoiding patient discrimination due to limited data on endpoints.

The need to consider the best interests of patients in the drug innovation mission. Agencies must ensure that the benefit-risk balance is positive.

Potential advantages and challenges of project Orbis.

The Cancer Drug Development Forum

WEBINAR

TREATMENT OF CANCER PATIENTS DURING THE SARS-COV2 PANDEMIC: IMPLICATIONS FOR CLINICAL TRIALS

WEBINAR | 2 APRIL 2020

PROF. DR. MARIE VON LILIENFELD-TOAL, UNIVERSITY JENA, GERMANY

Oncology clinical trial performance has been severely affected by the COVID-19 pandemic. Most researchers have stopped recruitment and the reduction in currently available standard treatments for cancer patients, has also rendered trials outcomes difficult to assess. Regulatory agencies have already published guidance documents that call for revised risk assessment.

WEBINAR

APPLICATION OF ARTIFICIAL INTELLIGENCE IN LEUKEMIA DIAGNOSTICS: IMPLICATIONS FOR CLINICAL TRIALS AND CANCER DRUG DEVELOPMENT

WEBINAR | 15 OCTOBER 2020

PROF. DR. TORSTEN HAFERLACH, MLL MUNICH LEUKEMIA LABORATORY, GERMANY

Leukaemia diagnostics depends on phenotypes and experienced personnel. The new options of artificial intelligence, machine learning and cloud computing offer fascinating options to achieve better diagnostic accuracy and improved therapeutic selection. This talk demonstrated how these technologies are already used in a routine, accredited workflow and how they may change future drug development for haematological malignancies.

WEBINAR

MATCHING ENDPOINTS AND OBJECTIVES IN CLINICAL TRIALS: REFLECTIONS ON DISCONNECTS AND OPPORTUNITIES

WEBINAR I 1 DECEMBER 2020

ARMIN SCHÜLER, MERCK, GERMANY

The webinar assessed the importance to contextualise endpoints and objectives and the associated opportunities for clinical drug development. At the end of a trial it's often just stated "The trial met it's endpoint". However, what about the primary objective of the trial? Are the results relevant for the stakeholders? Is a clear interpretation of the results possible? The estimands framework as introduced in ICH E9 (R1) offers a systematic approach to design clinicals trials, which are better able to answer the clinical question ultimately leading to a higher probability of success.

WEBINAR

PATIENT ACCESS TO NEWLY REGISTERED ANTICANCER AGENTS

WEBINAR I 9 DECEMBER 2020

PROF. CARIN A. UYL-DE GROOT, ERASMUS UNIVERSITY ROTTERDAM, NETHERLANDS

Many new cancer medicines have been developed that can improve patients' outcomes. However, access to these agents usually takes longer in Europe than in the United States (US), and varies greatly across EU countries. The aim of this webinar was to discuss the actual access to several recently registered cancer drugs in European countries following EMA marketing authorisation, and the implications for patients.

CDDF AGENDA 2021

2021 events focus on current and future challenges impacting cancer drug development

WEBINAR

FROM TREATMENT DEVELOPMENT TO HEALTHCARE: IS THE CONTINUUM BECOMING A REALITY?

WEBINAR I 28 JANUARY 2021

DR. DENIS LACOMBE, EORTC, BELGIUM

The needs of patients in healthcare systems should define the research priorities. Many questions do remain unaddressed when new technologies are approved. Optimizing their use in the healthcare systems such as but not limited to combination, sequence, duration, de-escalation, or adjusting the right population-based on clinically validated biomarkers needs robust datasets addressing medically relevant end-points. Multidisciplinary pragmatic clinical research addressing such questions, traditionally performed by the non-commercial sector is at the cornerstone between treatment development and access. Delivering datasets informative to patients, doctors, HTA bodies and payers should be integral to the process of treatment development into the healthcare system to address the gap efficacy- effectiveness. Re-engineering the process while integrating new solutions for data access is bound to methodological and economical challenges amongst others, which have been addressed at the Webinar.

VIRTUAL CONFERENCE

CDDF 12TH SPRING CONFERENCE

VIRTUAL CONFERENCE I 8-10 FEBRUARY 2021

OBJECTIVES

To understand the pitfalls in the European HTA process leading to current inequality in patient access.

To face forward discussion on endpoints in cancer clinical trials, and on digital tools and use of artificial intelligence in cancer drug development.

To understand current differences in the global regulatory approval and HTA approaches, and discussing potentials for harmonization.

To raise awareness on novel methods for clinical oncology imaging, and discussion on their application as biomarkers in the drug development process.

To address regulatory guidance: EMA regulatory strategy 2025; envisioning product development for 2025; Industry perspectives on innovation and current topics in oncology.

ONLINE WORKSHOP
ENDPOINTS IN CANCER DRUG DEVELOPMENT

ONLINE WORKSHOP | 26 - 28 APRIL 2021

OBJECTIVES

To understand past achievements and current challenges in the definition and assessment of endpoints.

To update the knowledge on novel endpoints, like measurable residual disease or circulating tumor nucleotides, and possible pathways for validation.

To understand strategies to improve the use and overcome obstacles in the use of patient-reported outcomes in cancer drug development.

To develop awareness for the use of endpoints in expedited regulatory pathways.

WORKSHOP
DIGITAL TOOLS AND ARTIFICIAL INTELLIGENCE IN CANCER DRUG DEVELOPMENT

AMSTERDAM, THE NETHERLANDS | 27 – 28 SEPTEMBER 2021

OBJECTIVES

To understand the current landscape of use to digital tools in cancer drug development.

To explore regulatory aspects, challenges and plans for formal registration of digital tools from trial data.

To learn about the various digital options to support trials and improve data collection and outcomes.

WORKSHOP
GENE-CELL THERAPY IN ONCOLOGY

AMSTERDAM, THE NETHERLANDS | 29 – 30 NOVEMBER 2021

CDDF INDUSTRY PARTNERS PLATFORM

WHAT IS THE CDDF INDUSTRY PARTNERS PLATFORM?

The CDDF Industry Partners Platform is composed of large and SME partners from the pharmaceutical industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Partners Platform acts as an advisory body within CDDF and supports the association in compliance with all relevant regulations and in a manner consistent with the non-competitive, non-commercial platform that CDDF offers to all stakeholders.

WHY JOIN THE CDDF INDUSTRY PARTNERS PLATFORM?

- Stimulate advancement in oncology treatment and delivery
- Identify and overcome challenges in the development of cancer drugs
- Improve product time to market for new treatments

CONTRIBUTE TO THE **DEVELOPMENT** OF **CANCER DRUGS** AND **TREATMENT**

BECOME A PARTNER OF THE CDDF

INDUSTRY PARTNER BENEFITS

1. **Access the CDDF Industry Partners Platform** where pharmaceutical partners meet to discuss industry perspectives on the challenges to be addressed in cancer drug development.
2. **3 free registrations to every CDDF event** (one free registration per event for SME partner).
3. **Livestream access** to CDDF workshops and conference on the condition that at least two delegates (or one SME delegate) are present in person at the event.
4. **Early access to digital content** from the conference and workshops for one year before general release.
5. **Contribute to CDDF's scientific programme** and coordinate event programmes alongside academics and regulators.
6. Access to a **reputable oncology network** and the opportunity to connect informally with representatives from **academia, regulatory authorities, HTAs, and patient groups.**

ANNUAL CONTRIBUTION

CDDF funding is managed according to strict rules for non-profit organisations allowing it to act as an independent entity.

Main pharmaceutical partner contribution
Annual contribution: 40,000 EUR

Small and Medium-sized Enterprise (SME) pharmaceutical partner contribution
Annual contribution: 7,000 EUR

Do I qualify as a small pharmaceutical partner?

The CDDF understands the challenges SMEs face in getting their drugs on the market. We facilitate opportunities to advance drug access and delivery by providing important learning and networking opportunities to help your company streamline the process of making treatment available.

A pharmaceutical partner is considered to be an SME if it has no drug on the market or if it meets the definition of the European Commission for an SME: *https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en*

If you would like to join the CDDF Industry Partner Platform, please contact us at

info@cddf.org

COLLABORATION IS THE **KEY** TO IMPROVING OUTCOMES FOR **CANCER PATIENTS**

info@cddf.org

www.cddf.org

@cddf_eu

The Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl, Clos Chapelle-aux-Champs 30,
1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752